163 related articles for article (PubMed ID: 35385323)
1. Structural and conformational studies of biased agonism through formyl peptide receptors.
Liao Q; Ye RD
Am J Physiol Cell Physiol; 2022 May; 322(5):C939-C947. PubMed ID: 35385323
[TBL] [Abstract][Full Text] [Related]
2. Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling.
Zhang S; Gong H; Ge Y; Ye RD
Pharmacol Res; 2020 Nov; 161():105117. PubMed ID: 32768626
[TBL] [Abstract][Full Text] [Related]
3. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
Stepniewski TM; Filipek S
Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
[TBL] [Abstract][Full Text] [Related]
4. Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2.
Zhuang Y; Wang L; Guo J; Sun D; Wang Y; Liu W; Xu HE; Zhang C
Nat Commun; 2022 Feb; 13(1):1054. PubMed ID: 35217703
[TBL] [Abstract][Full Text] [Related]
5. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomic analysis sheds light on intracellular signaling cascades triggered by Formyl-Peptide Receptor 2.
Cattaneo F; Russo R; Castaldo M; Chambery A; Zollo C; Esposito G; Pedone PV; Ammendola R
Sci Rep; 2019 Nov; 9(1):17894. PubMed ID: 31784636
[TBL] [Abstract][Full Text] [Related]
7. Structure of formylpeptide receptor 2-G
Zhuang Y; Liu H; Edward Zhou X; Kumar Verma R; de Waal PW; Jang W; Xu TH; Wang L; Meng X; Zhao G; Kang Y; Melcher K; Fan H; Lambert NA; Eric Xu H; Zhang C
Nat Commun; 2020 Feb; 11(1):885. PubMed ID: 32060286
[TBL] [Abstract][Full Text] [Related]
8. Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors.
Merlin J; Park J; Vandekolk TH; Fabb SA; Allinne J; Summers RJ; Langmead CJ; Riddy DM
Mol Pharmacol; 2022 Apr; 101(4):246-256. PubMed ID: 35125345
[TBL] [Abstract][Full Text] [Related]
9. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
10. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
Gabl M; Holdfeldt A; Sundqvist M; Lomei J; Dahlgren C; Forsman H
Biochem Pharmacol; 2017 Dec; 145():114-122. PubMed ID: 28855087
[TBL] [Abstract][Full Text] [Related]
11. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
12. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.
Ge Y; Zhang S; Wang J; Xia F; Wan JB; Lu J; Ye RD
FASEB J; 2020 May; 34(5):6920-6933. PubMed ID: 32239559
[TBL] [Abstract][Full Text] [Related]
13. Basic characteristics of the neutrophil receptors that recognize formylated peptides, a danger-associated molecular pattern generated by bacteria and mitochondria.
Dahlgren C; Gabl M; Holdfeldt A; Winther M; Forsman H
Biochem Pharmacol; 2016 Aug; 114():22-39. PubMed ID: 27131862
[TBL] [Abstract][Full Text] [Related]
14. Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization.
Sogawa Y; Ohyama T; Maeda H; Hirahara K
J Pharmacol Sci; 2011; 115(1):63-8. PubMed ID: 21173551
[TBL] [Abstract][Full Text] [Related]
15. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of ligand binding modes at the human formyl peptide receptor 2.
Chen T; Xiong M; Zong X; Ge Y; Zhang H; Wang M; Won Han G; Yi C; Ma L; Ye RD; Xu Y; Zhao Q; Wu B
Nat Commun; 2020 Mar; 11(1):1208. PubMed ID: 32139677
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.
He HQ; Troksa EL; Caltabiano G; Pardo L; Ye RD
J Biol Chem; 2014 Jan; 289(4):2295-306. PubMed ID: 24285541
[TBL] [Abstract][Full Text] [Related]
19. Insights into the Activation Mechanism of the ALX/FPR2 Receptor.
Schmitz Nunes V; Rogério AP; Abrahão O
J Phys Chem Lett; 2020 Nov; 11(21):8952-8957. PubMed ID: 33030905
[TBL] [Abstract][Full Text] [Related]
20. Chemotactic Ligands that Activate G-Protein-Coupled Formylpeptide Receptors.
Krepel SA; Wang JM
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
